Randomised, Double-Blind, Placebo-Controlled Study on the Efficacy and Tolerance of Trospium Chloride in Patients with Motor Urge Incontinence

Authors: Ulshöfer B.1; Bihr A-M.2; Bödeker R-H.3; Schwantes U.2; Jahn H-P.1

Source: Clinical Drug Investigation, Volume 21, Number 8, 1 August 2001 , pp. 563-569(7)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Objective: Trospium chloride is an antimuscarinic drug with a quaternary ammonium structure for the treatment of detrusor instability and hyper-reflexia. It is generally considered to be well tolerated, but exhibits poor gastrointestinal absorption after oral administration. This study was conducted to assess the efficacy and safety of trospium chloride 15mg three times daily for 28 days in patients with motor urge incontinence.

Design: Multicentre, double-blind, randomised, placebo-controlled study.

Patients and Participants: 46 patients with motor urge incontinence.

Methods: Patients were treated either with trospium chloride-coated tablets 15mg or placebo, administered three times daily for 28 days. The main parameter was the change in maximum bladder capacity as determined by cystometry before and after treatment. The occurrence and frequency of adverse events during treatment were assessed as secondary parameters.

Results: Pretreatment values for maximum bladder capacity were comparable in the two groups (trospium chloride: 174.7ml, placebo: 206.2ml; p = 0.21). In patients assessed by per-protocol analysis, the mean maximum bladder capacity increased by 82.3ml in patients receiving trospium chloride therapy, but decreased slightly (-4.1ml; p le 0.01) in the placebo group. Dry mouth was reported as an adverse event 11 times in the trospium chloride group and 7 times in the placebo group (p = 0.41). Other adverse events were rarely observed in the two treatment groups (0 to 3 times).

Conclusion: In this controlled clinical study in patients with urodynamically verified motor urge incontinence, treatment with trospium chloride 15mg three times daily for 28 days led to a significant increase in maximum bladder capacity compared with placebo treatment. There were no differences in the frequency of adverse events in the treatment group compared with the placebo group.

Keywords: Muscarinic receptor antagonists, therapeutic use; Trospium chloride, therapeutic use; Urge incontinence, treatment

Document Type: Original article

Affiliations: 1: Department of Urology, Klinikum Erfurt, Erfurt, Germany 2: Department of Medical Science/Clinical Research, Dr R. Pfleger GmbH, Bamberg, Germany 3: Statistics Team, Institute of Medical Informatics, Justus Liebig University, Giebetaen, Germanyen, Germany">

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$62.95 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A